MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

Inclusion Criteria: * CT findings showing mixed ground-glass or solid lesions, histologically or cytologically confirmed as NSCLC, with clinical stages Ia, Ib, or IIa (size ≤5 cm, T1-T2N0M0) according to the 9th edition of TNM classification. * EGFR exon 19 deletion or exon 21 L858R mutation. * Age ≥18 years. * ECOG PS score of 0-2. * Expected survival ≥3 months. * Deemed unsuitable for or refusal of surgery/radiotherapy after multidisciplinary discussion. * No prior EGFR-TKI targeted therapy. * Willing to undergo initial ablation therapy, with good compliance to examinations and follow-ups, and able to understand the study and provide informed consent. Exclusion Criteria: * Severe liver, kidney, heart, lung, or brain dysfunction or other comorbidities that preclude tolerance to MWA or targeted therapy. * Chest CT findings indicating percutaneous inaccessibility of the lung lesion for MWA. * Platelet count \<50×10⁹/L, severe bleeding tendency, or uncorrectable coagulation disorders. * Current or prior (within 3 months) use of anti-tumor drugs or EGFR-TKI therapy. * Uncontrolled conditions (including but not limited to non-pulmonary malignancies, active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, psychiatric disorders, etc.). * Pregnant or breastfeeding women, or those planning pregnancy during the study. * Other conditions deemed by the investigator as unsuitable for study participation.